RCEL Stock — Avita Medical Ltd

Avita Medical Ltd (RCEL)

Updated October 16, 2026.

RCEL is a Stock. Its deepest 1-year drawdown was 39.2%.

AVITA Medical operates as a therapeutic acute wound care company, developing and commercializing the RECELL System—a cell harvesting device used to treat thermal burns, full-thickness skin defects, and vitiligo—along with related products and biosynthetic wound matrices. The company does not currently have an established distribution schedule. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom, and appeals primarily to growth-oriented investors in the medical device sector rather than income-focused investors.

RCEL performance

Returns are updating. RCEL's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 39.2%.

RCEL key facts

Asset type

Stock

Asset class

Equity

Inception date

03/29/2012

Distribution frequency

None

Last close

$13.04 (as of 2026-10-16)

Market cap

$403,286,085

Average volume

318348.0

Beta

1.987

Payout ratio

0.0%

Forward P/E

10.2881

EPS

$-1.43

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RCEL risks and drawbacks

The deepest 1-year drawdown on record here is 39.2%.

Who may consider RCEL — and who may not

It is a weaker fit for investors who need monthly cash flow (RCEL does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on RCEL

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions